Who is Taking Ozempic for Weight Loss? Exploring the Trend

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has transformed weight loss treatment since its FDA approval for chronic weight management in 2021, helping patients reduce body weight by an average of 15% over 68 weeks in clinical trials. Today, the medication appeals to a broad demographic—from people with obesity and type 2 diabetes to individuals seeking metabolic support—making it one of the most requested therapies in precision health. Understanding who uses semaglutide and why can help you determine if this GLP-1 therapy aligns with your health goals.

The Demographics of Semaglutide Users Today

Semaglutide users span a wide age range, though uptake has been particularly strong among adults aged 30 to 60 who have struggled with weight management despite diet and exercise. Many users have a BMI above 30 or a BMI above 27 with weight-related health conditions like hypertension, elevated cholesterol, or prediabetes. What unites this diverse group is a shared frustration with traditional weight loss methods and a willingness to explore pharmaceutical options backed by clinical evidence.

Beyond medical indication, semaglutide appeals to people who value data-driven treatment and personalization. Users often report that they've tried multiple diet programs, fitness regimens, or other medications without sustained results. The medication works by signaling the brain's appetite control centers, reducing hunger and food cravings in ways that behavioral change alone may not achieve. This mechanism makes semaglutide particularly attractive to those seeking a biological approach rather than relying solely on willpower.

Why Demand for Semaglutide Has Surged

Media coverage and celebrity endorsements have elevated awareness of semaglutide, but clinical evidence is the true driver of demand. The STEP trials demonstrated that patients receiving semaglutide lost significantly more weight than those on placebo, with many experiencing improvements in blood sugar control and cardiovascular risk markers. Healthcare providers now recognize semaglutide as a legitimate tool for addressing metabolic dysfunction, not just cosmetic weight loss.

Insurance barriers have historically limited access, creating long wait lists and patient frustration. PlexusDx responds to this gap by offering compounded semaglutide injections through licensed 503A pharmacies, eliminating insurance requirements and membership fees. This approach has democratized access, allowing motivated patients to begin treatment within days rather than months. HSA and FSA accounts also cover PlexusDx medications, providing additional financial flexibility.

Medical Conditions Driving Semaglutide Adoption

Patients with type 2 diabetes represent a significant portion of semaglutide users, as the medication lowers blood sugar while promoting weight loss—a dual benefit few therapies offer. Individuals with metabolic syndrome, characterized by high blood pressure, elevated fasting glucose, and excess abdominal fat, also benefit from semaglutide's multi-system effects. Cardiometabolic risk reduction, beyond weight loss alone, has made semaglutide attractive to people seeking prevention of heart disease and stroke.

Polycystic ovary syndrome (PCOS), nonalcoholic fatty liver disease (NAFLD), and sleep apnea are additional conditions where semaglutide has shown clinical promise. Users with these diagnoses often experience improvements in insulin sensitivity, hormonal balance, and respiratory function as weight decreases. The medication's ability to address underlying metabolic drivers rather than just symptoms appeals to patients pursuing root-cause treatment.

Personalization and Genetic Insights in Semaglutide Response

Individual variation in semaglutide response is substantial—some users lose 10% of body weight while others exceed 20%, depending on genetics, lifestyle, and medication tolerance. PlexusDx offers the Precision Peptide Genetic Test, which maps 14 pathways and 49 peptides to identify how your unique genetic makeup influences GLP-1 sensitivity and response. Key variants like GIPR rs1800437 affect how effectively your body signals fullness and metabolic rate, directly shaping treatment outcomes.

Understanding your genetic predisposition allows PlexusDx clinicians to optimize your starting dose and titration schedule, maximizing efficacy while minimizing side effects. The test costs $298, providing personalized insights that guide long-term medication strategy. This approach transforms semaglutide from a one-size-fits-all therapy into a precision tool tailored to your biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What type of patient typically benefits most from semaglutide?

Patients with a BMI above 30, or above 27 with weight-related health conditions, tend to see the most benefit. However, semaglutide also works well for people with type 2 diabetes, metabolic syndrome, or PCOS seeking both weight loss and metabolic improvement. PlexusDx serves all of these populations without requiring insurance approval or lengthy waiting periods.

How much weight do semaglutide users typically lose?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is semaglutide only for people with diabetes?

No. While semaglutide was initially approved for type 2 diabetes, it gained FDA approval for chronic weight management in people without diabetes in 2021. PlexusDx serves both populations—users managing blood sugar and those seeking weight loss and metabolic health improvements.

What are the most common side effects users experience?

Nausea is the most frequently reported side effect, especially during the first weeks of treatment, though it typically decreases over time. Gastrointestinal symptoms like constipation or diarrhea can occur. Most users find side effects manageable and transient, and PlexusDx clinicians adjust dosing to optimize tolerability while maintaining efficacy.

How does PlexusDx's pricing work for semaglutide?

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with no insurance required and no membership fees. Your dose may increase over time as your body adjusts, but your monthly price remains flat across our commitment tiers. The medication is HSA and FSA eligible, providing additional savings.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test identifies variants in GIPR and FTO, and MC4R genes that influence semaglutide response and weight loss potential. For $298, you gain insights into 14 pathways and 49 peptides, allowing personalized dose optimization and realistic outcome expectations.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.